Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 2/2019

08.11.2018 | Original Article

Interpretation of very low avidity indices acquired with the Liaison XL Toxo IgG avidity assay in dating toxoplasmosis infection

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Congenital toxoplasmosis is an important cause of complications in pregnancy. Toxoplasmosis is often asymptomatic and thus serological tests are usually performed to screen for it. A first serum which exhibit both IgG and IgM may be due to nascent toxoplasmosis seroconversion, non-specific IgM reaction, or residual IgM. The IgG avidity test has been proposed to identify latent infections. A high index excludes recent toxoplasmosis whereas an intermediate or low index only suggests a recent infection, the caveats being that some people with latent Toxoplasma gondii infection show IgG with low or intermediate avidity. In this study, we investigated the ability of the Liaison XL Toxo IgG avidity (DiaSorin, Saluggia, Italy) assay to confirm recent infection when IgG avidity index is very low (≤ 0.1). Four thousand two hundred ninety-seven sera exhibiting both IgG and IgM were included and avidity was performed on the Liaison device according to the manufacturer’s recommendations. One hundred twenty-six sera on the 297 sera which exhibited very low IgG avidity indices (≤ 0.1) could be exploited: 97% of sera with IgG avidity indices < 0.05 actually corresponded to recent infection (less than 3 months). A similar but less pronounced trend was observed for the sera exhibiting indices between 0.05 and 0.1 (69% corresponded to recent infections). The IgG avidity index data we obtained with the Liaison XL Toxo device are similar to those obtained with other devices. This body of consistent results underlines the interest of very low IgG avidity indices as a sign of probable recent toxoplasmosis.
Literatur
2.
Zurück zum Zitat Yera H, Paris L, Bastien P, Candolfi E (2015) Diagnostic biologique de la toxoplasmose congénitale. Rev Fr Lab 2015(470):65–72 Yera H, Paris L, Bastien P, Candolfi E (2015) Diagnostic biologique de la toxoplasmose congénitale. Rev Fr Lab 2015(470):65–72
3.
Zurück zum Zitat Fricker-Hidalgo H, L’Ollivier C, Bosson C, Imbert S, Bailly S, Dard C et al (2017) Interpretation of the Elecsys Toxo IgG avidity results for very low and very high index: study on 741 sera with a determined date of toxoplasmosis. Eur J Clin Microbiol Infect Dis 36(5):847–852CrossRefPubMed Fricker-Hidalgo H, L’Ollivier C, Bosson C, Imbert S, Bailly S, Dard C et al (2017) Interpretation of the Elecsys Toxo IgG avidity results for very low and very high index: study on 741 sera with a determined date of toxoplasmosis. Eur J Clin Microbiol Infect Dis 36(5):847–852CrossRefPubMed
4.
Zurück zum Zitat Dardé M-L, Peyron F (2012) Toxoplasme et toxoplasmose. EMC - Pédiatrie - Maladies infectieuses 7(4):1–12CrossRef Dardé M-L, Peyron F (2012) Toxoplasme et toxoplasmose. EMC - Pédiatrie - Maladies infectieuses 7(4):1–12CrossRef
5.
Zurück zum Zitat Gras L, Gilbert RE, Wallon M, Peyron F, Cortina-Borja M (2004) Duration of the IgM response in women acquiring Toxoplasma gondii during pregnancy: implications for clinical practice and cross-sectional incidence studies. Epidemiol Infect 132(3):541–548CrossRefPubMedPubMedCentral Gras L, Gilbert RE, Wallon M, Peyron F, Cortina-Borja M (2004) Duration of the IgM response in women acquiring Toxoplasma gondii during pregnancy: implications for clinical practice and cross-sectional incidence studies. Epidemiol Infect 132(3):541–548CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Villard O, Breit L, Cimon B, Franck J, Fricker-Hidalgo H, Godineau N et al (2013) Comparison of four commercially available avidity tests for Toxoplasma gondii-specific IgG antibodies. Clin Vaccine Immunol 20(2):197–204CrossRefPubMedPubMedCentral Villard O, Breit L, Cimon B, Franck J, Fricker-Hidalgo H, Godineau N et al (2013) Comparison of four commercially available avidity tests for Toxoplasma gondii-specific IgG antibodies. Clin Vaccine Immunol 20(2):197–204CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Lachaud L, Calas O, Picot MC, Albaba S, Bourgeois N, Pratlong F (2009) Value of 2 IgG avidity commercial tests used alone or in association to date toxoplasmosis contamination. Diagn Microbiol Infect Dis 64(3):267–274CrossRefPubMed Lachaud L, Calas O, Picot MC, Albaba S, Bourgeois N, Pratlong F (2009) Value of 2 IgG avidity commercial tests used alone or in association to date toxoplasmosis contamination. Diagn Microbiol Infect Dis 64(3):267–274CrossRefPubMed
8.
Zurück zum Zitat Flori P, Chene G, Varlet MN, Sung RT (2009) Toxoplasma gondii serology in pregnant woman: characteristics and pitfalls. Ann Biol Clin 125–133 Flori P, Chene G, Varlet MN, Sung RT (2009) Toxoplasma gondii serology in pregnant woman: characteristics and pitfalls. Ann Biol Clin 125–133
9.
Zurück zum Zitat Hedman K, Lappalainen M, Seppaia I, Makela O (1989) Recent primary toxoplasma infection indicated by a low avidity of specific IgG. J Infect Dis 159(4):736–740CrossRef Hedman K, Lappalainen M, Seppaia I, Makela O (1989) Recent primary toxoplasma infection indicated by a low avidity of specific IgG. J Infect Dis 159(4):736–740CrossRef
10.
Zurück zum Zitat Soula F, Fréalle E, Durand-Joly I, Dutoit E, Rouland V, Renard E et al (2007) Intérêt de l’indice d’avidité des IgG pour le diagnostic d’exclusion d’une toxoplasmose récente: comparaison de la trousse Toxo IgG Avidité SFRI® à la trousse Toxo IgG Avidity Vidas®. Ann Biol Clin 257–264 Soula F, Fréalle E, Durand-Joly I, Dutoit E, Rouland V, Renard E et al (2007) Intérêt de l’indice d’avidité des IgG pour le diagnostic d’exclusion d’une toxoplasmose récente: comparaison de la trousse Toxo IgG Avidité SFRI® à la trousse Toxo IgG Avidity Vidas®. Ann Biol Clin 257–264
11.
Zurück zum Zitat Peyron F, Mc Leod R, Ajzenberg D, Contopoulos-Ioannidis D, Kieffer F, Mandelbrot L et al (2017) Congenital toxoplasmosis in France and the United States: one parasite, two diverging approaches. Torgerson PR, éditeur. PLOS Negl Trop Dis 11(2):e0005222 Peyron F, Mc Leod R, Ajzenberg D, Contopoulos-Ioannidis D, Kieffer F, Mandelbrot L et al (2017) Congenital toxoplasmosis in France and the United States: one parasite, two diverging approaches. Torgerson PR, éditeur. PLOS Negl Trop Dis 11(2):e0005222
12.
Zurück zum Zitat Sickinger E, Gay-Andrieu F, Jonas G, Schultess J, Stieler M, Smith D et al (2008) Performance characteristics of the new ARCHITECT Toxo IgG and Toxo IgG avidity assays. Diagn Microbiol Infect Dis 62(3):235–244CrossRefPubMed Sickinger E, Gay-Andrieu F, Jonas G, Schultess J, Stieler M, Smith D et al (2008) Performance characteristics of the new ARCHITECT Toxo IgG and Toxo IgG avidity assays. Diagn Microbiol Infect Dis 62(3):235–244CrossRefPubMed
13.
Zurück zum Zitat Jost C, Touafek F, Fekkar A, Courtin R, Ribeiro M, Mazier D et al (2011) Utility of immunoblotting for early diagnosis of toxoplasmosis seroconversion in pregnant women. Clin Vaccine Immunol 18(11):1908–1912CrossRefPubMedPubMedCentral Jost C, Touafek F, Fekkar A, Courtin R, Ribeiro M, Mazier D et al (2011) Utility of immunoblotting for early diagnosis of toxoplasmosis seroconversion in pregnant women. Clin Vaccine Immunol 18(11):1908–1912CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Peyron F, Wallon M, Kieffer F, Garweg J (2016) Toxoplasmosis. In: Infectious Diseases of the Fetus and the Newborn Infant, pp 949–1042 Peyron F, Wallon M, Kieffer F, Garweg J (2016) Toxoplasmosis. In: Infectious Diseases of the Fetus and the Newborn Infant, pp 949–1042
15.
Zurück zum Zitat Murat J-B, L’Ollivier C, Fricker Hidalgo H, Franck J, Pelloux H, Piarroux R (2012) Evaluation of the new Elecsys Toxo IgG avidity assay for toxoplasmosis and new insights into the interpretation of avidity results. Clin Vaccine Immunol 19(11):1838–1843CrossRefPubMedPubMedCentral Murat J-B, L’Ollivier C, Fricker Hidalgo H, Franck J, Pelloux H, Piarroux R (2012) Evaluation of the new Elecsys Toxo IgG avidity assay for toxoplasmosis and new insights into the interpretation of avidity results. Clin Vaccine Immunol 19(11):1838–1843CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Petersen E, Borobio MV, Guy E, Liesenfeld O, Meroni V, Naessens A et al (2005) European multicenter study of the LIAISON automated diagnostic system for determination of toxoplasma gondii-specific immunoglobulin G (IgG) and IgM and the IgG avidity index. J Clin Microbiol 43(4):1570–1574CrossRefPubMedPubMedCentral Petersen E, Borobio MV, Guy E, Liesenfeld O, Meroni V, Naessens A et al (2005) European multicenter study of the LIAISON automated diagnostic system for determination of toxoplasma gondii-specific immunoglobulin G (IgG) and IgM and the IgG avidity index. J Clin Microbiol 43(4):1570–1574CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Candolfi E, Pastor R, Huber R, Filisetti D, Villard O (2007) IgG avidity assay firms up the diagnosis of acute toxoplasmosis on the first serum sample in immunocompetent pregnant women. Diagn Microbiol Infect Dis 58(1):83–88CrossRefPubMed Candolfi E, Pastor R, Huber R, Filisetti D, Villard O (2007) IgG avidity assay firms up the diagnosis of acute toxoplasmosis on the first serum sample in immunocompetent pregnant women. Diagn Microbiol Infect Dis 58(1):83–88CrossRefPubMed
18.
Zurück zum Zitat Wallon M, Peyron F, Cornu C, Vinault S, Abrahamowicz M, Kopp CB et al (2013) Congenital toxoplasma infection: monthly prenatal screening decreases transmission rate and improves clinical outcome at age 3 years. Clin Infect Dis 56(9):1223–1231CrossRefPubMed Wallon M, Peyron F, Cornu C, Vinault S, Abrahamowicz M, Kopp CB et al (2013) Congenital toxoplasma infection: monthly prenatal screening decreases transmission rate and improves clinical outcome at age 3 years. Clin Infect Dis 56(9):1223–1231CrossRefPubMed
19.
Metadaten
Titel
Interpretation of very low avidity indices acquired with the Liaison XL Toxo IgG avidity assay in dating toxoplasmosis infection
Publikationsdatum
08.11.2018
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 2/2019
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-018-3421-5

Weitere Artikel der Ausgabe 2/2019

European Journal of Clinical Microbiology & Infectious Diseases 2/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.